Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 3(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01766076Phase 3Completed

Atorvastatin for HAART Suboptimal Responders

Role: collaborator

NCT02176135Phase 1Withdrawn

Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

Role: lead

NCT02017587Unknown

Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection

Role: lead

NCT02031874Completed

Immunogenicity of Inactivated Swine H1N1 Vaccine In HIV Infected Children - The Miami Cohort Study

Role: collaborator

All 4 trials loaded